| Sharel A Martin, MD | |
|
325 Butts Ave, Tomah, WI 54660-1412 | |
| (608) 372-5951 | |
| (608) 372-3436 |
| Full Name | Sharel A Martin |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 325 Butts Ave, Tomah, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114917648 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 37339 (Wisconsin) | Secondary |
| 207P00000X | Emergency Medicine | 37339-20 (Wisconsin) | Primary |
| Entity Name | Tomah Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992970453 PECOS PAC ID: 6901897016 Enrollment ID: O20040519000123 |
News Archive
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010.
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report. The findings in nine people, most of whom had failed all other treatments, suggest new ways to treat a disease that tends to progress relentlessly.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Researchers in the School of Dentistry at The University of Manchester have created a unique way of identifying osteoporosis sufferers from ordinary dental x-rays.
› Verified 5 days ago
| Entity Name | Tomah Memorial Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1184765240 PECOS PAC ID: 6901897016 Enrollment ID: O20101120000172 |
News Archive
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010.
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report. The findings in nine people, most of whom had failed all other treatments, suggest new ways to treat a disease that tends to progress relentlessly.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Researchers in the School of Dentistry at The University of Manchester have created a unique way of identifying osteoporosis sufferers from ordinary dental x-rays.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sharel A Martin, MD 325 Butts Ave, Tomah, WI 54660-1412 Ph: (608) 372-5951 | Sharel A Martin, MD 325 Butts Ave, Tomah, WI 54660-1412 Ph: (608) 372-5951 |
News Archive
Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010.
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report. The findings in nine people, most of whom had failed all other treatments, suggest new ways to treat a disease that tends to progress relentlessly.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Researchers in the School of Dentistry at The University of Manchester have created a unique way of identifying osteoporosis sufferers from ordinary dental x-rays.
› Verified 5 days ago
Adam J Haggerty, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 321 Butts Ave, Tomah, WI 54660 Phone: 608-372-2181 | |
Dr. Emile W. Salvo, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 17312 Interlude Rd, Tomah, WI 54660 Phone: 608-372-4564 |